Cross-reactive carbohydrate determinant-specific IgE obscures true atopy and exhibits α-1,3-fucose epitope-specific inverse associations with asthma

Gyaviira Nkurunungi1,2 | Harriet Mpairwe1 | Serge A. Versteeg3 |
Angela van Diepen4 | Jacent Nassuuna1 | Joyce Kabagenyi1 | Irene Nambuya1 |
Richard E. Sanya1,5 | Margaret Nampijja1 | Sonia Serna6 | Niels-Christian Reichardt6,7 |
Cornelis H. Hokke4 | Emily L. Webb8 | Ronald van Ree3 | Maria Yazdanbakhsh4 |
Alison M. Elliott1,2

Abstract

Background: In high-income, temperate countries, IgE to allergen extracts is a risk factor for, and mediator of, allergy-related diseases (ARDs). In the tropics, positive IgE tests are also prevalent, but rarely associated with ARD. Instead, IgE responses to ubiquitous cross-reactive carbohydrate determinants (CCDs) on plant, insect and parasite glycoproteins, rather than to established major allergens, are dominant. Because anti-CCD IgE has limited clinical relevance, it may impact ARD phenotyping and assessment of contribution of atopy to ARD.

Methods: Using an allergen extract-based test, a glycan and an allergen (glyco)protein microarray, we mapped IgE fine specificity among Ugandan rural Schistosoma mansoni (Sm)-endemic communities, proximate urban communities, and importantly in asthmatic and nonasthmatic schoolchildren.

Results: Overall, IgE sensitization to extracts was highly prevalent (43%-73%) but allergen arrays indicated that this was not attributable to established major allergenic components of the extracts (0%-36%); instead, over 40% of all participants recognized CCD-bearing components. Using glycan arrays, we dissected IgE responses to specific glycan moieties and found that reactivity to classical CCD epitopes (core β-1,2-xylose, α-1,3-fucose) was positively associated with sensitization to extracts, rural environment and Sm infection, but not with skin reactivity to extracts or sensitization to their major allergenic components. Interestingly, we discovered that reactivity to only a subset of core α-1,3-fucose-carrying N-glycans was inversely associated with asthma.
INTRODUCTION

In high-income countries, IgE to standard allergen extracts is a risk factor for, and mediator of, allergy-related diseases, including asthma, and defines "atopic" allergy-related disease phenotypes.1-3 In tropical low-income countries (LICs), allergen extract-specific IgE levels are often elevated, but rarely associated with allergy-related disease.4 Host immune responses to common allergen sources exhibit important parallels with responses to parasite, insect and other environmental exposures that have related molecular targets.5 For example, the Onchocerca volvulus tropomyosin protein is structurally homologous to house dust mite (HDM) tropomyosin and can induce basophil histamine release.6 Some Schistosoma mansoni (Sm) venom allergen-like (SmVAL) proteins (with orthologues in wasps) and tegumental allergen-like (SmTAL) proteins have allergenic properties.7,8 Recognition of such phenomena has provided insights regarding epidemiological trends of allergy in the tropics.9

The role of carbohydrate cross-reactivity in epidemiology of allergic sensitization and disease is less understood. Among the commonest sources of cross-reactivity between natural allergens and other environmental exposures are specific asparagine (N) linked glycan modifications found on some helminth, insect and plant proteins (termed cross-reactive carbohydrate determinants, CCDs). The N-glycan trimannosyl-chitobiose core (Man_3GlcNAc_2) is conserved in eukaryotes. "Classical" CCD N-glycans expressed by invertebrate and plant proteins,10,11 and on antigenic surfaces and in secretomes of schistosome eggs12 and some nematodes,13-16 carry additional, nonmammalian, IgE-binding motifs: 1) β-(1,2) xylose linked to the first mannose of the trimannosyl component and/or 2) α-(1,3) fucose.
linked to the asparagine-linked N-acetylgalacosamine (GlcNAc) of the glycans core.\textsuperscript{17,18} Glycoproteins carrying such N-glycans are potent immune determinants,\textsuperscript{10,19-22} inducing strong Th2-type responses,\textsuperscript{23} and comprising epitopes for antibodies,\textsuperscript{24-27} including IgE.\textsuperscript{28-30}

However, the relevance of these glycan motifs in allergy-related disease is unclear. Barring a few exceptions,\textsuperscript{31-33} anti-CCD IgE seems to have poor biological function: individuals with specific IgE to CCDs lack skin and oral reactivity to the same molecules.\textsuperscript{10,29,34}

In the tropics, CCDs have been reported to dominate specific IgE responses.\textsuperscript{4} Among Ghanaian schoolchildren, peanut-IgE-sensitization assessed by ImmunoCAP\textsuperscript{®} was prevalent and strongly associated with anti-CCD IgE and Schistosoma haematobium infection, but not clinical peanut allergy.\textsuperscript{35} The separation of anti-CCD IgE responses from clinical allergy symptoms, coupled with abundance of immunogenic CCDs on glycoproteins from environmental antigens prevalent in tropical settings (such as some schistosome antigens), led us to hypothesize an inverse association between anti-CCD IgE reactivity and clinical allergy, possibly indicative of CCD-mediated inhibition of allergic effector responses.

We conducted three studies in varied Ugandan settings to obtain a comparative assessment of allergy-related disease prevalence and risk factors in rural\textsuperscript{36} and urban\textsuperscript{37} settings, and among asthmatic children and controls.\textsuperscript{38} These studies provide an unprecedented opportunity to assess anti-CCD IgE profiles, their relevance to epidemiological trends of allergic sensitization and asthma, and their association with the rural-urban environment and Sm exposure in tropical LICs.

2 | METHODS

2.1 | Study design and population

The three studies comprised rural and urban cross-sectional surveys on allergy outcomes and a case-control study on asthma risk factors among schoolchildren in Uganda.

The rural survey (September 2015-August 2016) was conducted in Sm-endemic fishing villages of Koome islands, Lake Victoria, Uganda (Figure S1). It was the three-year outcome survey of the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases [LaVISWA; ISRCTN47196031\textsuperscript{39}], a cluster-randomized trial of community-wide standard versus intensive anthelmintic treatment.\textsuperscript{39,40} The urban survey (September 2016-September 2017) was conducted in Entebbe municipality, a lower helminth exposure, urban setting\textsuperscript{37} situated on northern shores of Lake Victoria (Figure S1).

The asthma study (May 2015-July 2017)\textsuperscript{38} enrolled children with doctor-diagnosed asthma and controls from schools in Entebbe and surrounding areas. All schoolchildren were screened using the International Study on Allergy and Asthma in Children (ISAAC) questionnaire.\textsuperscript{41} Children with a history of wheeze in the last year underwent a detailed clinical assessment by study clinicians, including a medical and treatment history, lung function tests, and were assessed for asthma control using the Asthma Control Test.\textsuperscript{38,42}

Among cases, 55.5% had well-controlled asthma, 29.5% partly controlled and 15% poorly controlled asthma. Only three cases had abnormal lung function tests. All cases were seen at one time point, started on the recommended treatment and were referred for additional management.\textsuperscript{42} Children in the same class as cases, with no history of wheezing, were eligible as controls. A Stata program (College Station, Texas, USA) was used to randomly select participants from each class register such that the number of controls was twice the number of cases.

Recent wheeze was also assessed in the rural and urban surveys using ISAAC questionnaires. Other procedures were identical in all three studies, including assessment of skin prick test (SPT) reactivity to allergens common in our setting\textsuperscript{43}: Dermatophagoides mix (D pteronyssinus and D farinae), Blomia tropicalis and Blattella germanica (ALK-Abelló; supplied by Laboratory Specialities [Pty] Ltd., South Africa). Visible flexural dermatitis [evaluated following Williams’ online manual\textsuperscript{44}], and questionnaire-determined recent rhinitis and urticarial rash were also assessed.

2.2 | Parasitological examinations

Infection with Sm and intestinal helminths was investigated using the Kato-Katz technique\textsuperscript{45} conducted on one stool sample per participant (two slides, read by different technicians). In the urban and rural surveys, stool was further examined for Strongyloides stercoralis infections using PCR,\textsuperscript{46,47} and urine for Sm circulating cathodic antigen (CCA, Rapid Medical Diagnostics, South Africa).

2.3 | Measurement of allergen- and glycan-specific IgE

The ImmunoCAP\textsuperscript{®} specific IgE test [Thermo Fisher Scientific, Uppsala, Sweden] (hereinafter “ImmunoCAP\textsuperscript{®}”) was used to measure plasma IgE levels to whole allergen extracts of house dust mite (D pteronyssinus, HDM), peanut (Arachis hypogaea) and German cockroach (Blattella germanica), with ≥ 0.35 kU/L defining allergic sensitization.\textsuperscript{48} The ImmunoCAP\textsuperscript{®} method is described in this article’s Supplementary information.

To assess IgE reactivity to established major allergenic components of these and other extracts, the ISAC (Immuno Solid-phase Allergen Chip) microarray [Thermo Fisher Scientific\textsuperscript{49-51} was used. The ISAC microarray comprised 112 allergen components from 51 sources. The binding assay is described in this article’s Supplementary information. The array comprises 67 recombinant components [produced in E coli, hence nonglycosylated\textsuperscript{52}]; and 45 components purified from natural extracts (denoted by prefix “n”, eg nMUXF3 for the glycan epitope from bromelain). Previous work has shown that nMUXF3 and glycoproteins from pollen (nPhi p 4, nCyn d 1, nPla a 2, nCry j 1, nCap a 1) and food (nJug r 2) are recognized by anti-CCD IgE, while other natural allergens on the ISAC are not.\textsuperscript{53} Herein,
“CCD-bearing components” denotes ISAC components confirmed to carry the classical core $\beta$-1,2-xyllose and/or $\alpha$-1,3-fucose substituted N-glycans. We also use the term "established major allergenic components" to refer to specific proteins that bind IgE to their protein backbone and are well-recognized as the molecular drivers of allergenic potency, in specific allergen sources.$^54,55$ Participants with an ISAC standardized unit (ISU) measurement of $\geq 0.3$ were considered sensitized to that allergen component.$^56,57$ Measurements were also reported as detectable versus undetectable (lower detection limit: 0.06 ISU).

A noncommercial microarray of 135 chemo-enzymatically synthesized glycans with and without $\beta$-1,2-xyllosylation and/or $\alpha$-1,3-fucosylation (Figure S2) was employed to measure plasma anti-glycan IgE. Microarray construction procedures have been published.$^58,59$ The IgE-binding assay and the microarray image processing procedures were adapted from previous studies$^{27,60-62}$ and are detailed in the Supplementary information. Median fluorescence intensities (MFIs) reported herein represent anti-glycan IgE concentrations, because fluorescence-labelled anti-human IgE was used to detect plasma IgE bound to individual glycans on the array.

Samples were also assessed for Schistosoma egg [SEA]- and adult worm [SWA] antigen-specific IgE, IgG and IgG4, by ELISA [described elsewhere$^{63}$].

2.4 | Statistical analysis

Statistical analyses were done in Stata 13.1, GraphPad Prism 7.0a (Fay Avenue, CA, USA) and R via the RStudio interface (version 1.1.383; Boston, USA). Initial analyses in the rural survey investigated the impact of trial intervention on IgE profiles using a cluster-level approach, as previously described.$^36$ Differences in characteristics between rural and urban survey participants and between asthmatic and nonasthmatic children were assessed using logistic or linear regression, allowing for the survey designs (clustering and weighting). Unadjusted analysis of differences in individual N-glycan-/- allergen-specific IgE levels between rural and urban participants, and between asthmatics and controls was done using the Mann-Whitney U test, correcting for multiple testing using a Monte Carlo simulation approach$^64$ with 1000 permutations, to generate empirical p values. For analyses comparing prevalences of ISAC-determined IgE sensitization between these groups, chi-squared tests (or Fisher’s exact test, for expected cell counts $< 5$) were used.

Since anti-glycan IgE responses were strongly correlated, they were further analysed using principal component analysis (PCA). Data for participants from all studies were pooled and principal component (PC) scores generated. Unadjusted and age- and sex-adjusted associations between PC scores and atopic sensitization, asthma status, Sm infection and survey setting were assessed using linear regression.

3 | RESULTS

3.1 | Participants’ characteristics

Allergen- and glycan-specific IgE measurements were conducted in a subset of randomly selected samples per study (Figure 1). Data on ImmunoCAP®-determined IgE sensitization were available for 780, 345 and 400 participants of the rural survey, urban survey and asthma study, respectively. For the rural survey, we present data combined from both anthelminthic treatment arms, because there was no effect of trial arm on ImmunoCAP®- or ISAC-determined IgE sensitization or on anti-glycan IgE reactivity (Table S1).$^{36}$

**FIGURE 1** Selection of samples for the ImmunoCAP® test and the ISAC and glycan microarray assays
| Characteristics                                      | Rural survey       | Urban survey       | PB | Case-control study on asthma in schoolchildren n/N (%) | Nonasthmatics | Asthmatics | P  |
|------------------------------------------------------|--------------------|--------------------|----|-------------------------------------------------------|---------------|------------|----|
| **Socio-demographic**                                |                    |                    |    |                                                       |               |            |    |
| Age in years, median (IQR)                           | 28 (21, 36)        | 22 (10, 32)        | .001 | 10 (8, 13)                                            | 11 (10, 14)   | .017       |    |
| Male sex                                             | 377/780 (46.4)     | 97/345 (28.1)      | <.001 | 94/200 (46.7)                                         | 92/200 (46.0) | .841       |    |
| **Allergy-related outcomes**                         |                    |                    |    |                                                       |               |            |    |
| **Skin prick test reactivity**                       |                    |                    |    |                                                       |               |            |    |
| Any                                                  | 164/780 (21.3)     | 72/336 (21.4)      | .955 | 60/198 (30.3)                                         | 105/198 (53.0) | <.001      |    |
| Dermatophagoides mix                                  | 87/780 (10.0)      | 61/336 (18.2)      | .003 | 47/198 (23.7)                                         | 91/198 (45.9) | <.001      |    |
| Blohmia tropicalis                                   | 54/780 (6.8)       | 41/336 (12.2)      | .025 | 45/198 (22.7)                                         | 90/198 (45.4) | <.001      |    |
| Blattella germanica                                  | 98/780 (13.9)      | 45/337 (13.4)      | .811 | 32/198 (16.2)                                         | 48/198 (24.2) | .046       |    |
| **asIgE sensitization (≥0.35 kU/L, ImmunoCAP)**      |                    |                    |    |                                                       |               |            |    |
| Any                                                  | 437/780 (55.1)     | 148/345 (42.9)     | .007 | 108/200 (54.0)                                        | 145/199 (72.9) | <.001      |    |
| D pteronyssinus                                      | 264/780 (33.2)     | 104/345 (30.1)     | .421 | 72/200 (36.0)                                         | 117/200 (58.5) | <.001      |    |
| Blattella germanica                                  | 393/780 (49.8)     | 118/345 (34.2)     | <.001 | 90/200 (45.0)                                         | 112/199 (56.3) | .025       |    |
| Arachis hypogaea                                     | 114/780 (14.9)     | 41/345 (11.9)      | .266 | 24/200 (12.0)                                         | 39/200 (19.5) | .041       |    |
| **asIgE concentration (kU/L, ImmunoCAP), median (IQR)** |                    |                    |    |                                                       |               |            |    |
| D pteronyssinus                                      | 0.2 (0.0, 0.6)     | 0.1 (0.0, 0.7)     | .229 | (0.0, 1.9)                                            | 1.0 (0.1, 3.75) | <.001      |    |
| Blattella germanica                                  | 0.4 (0.1, 1.5)     | 0.1 (0.0, 0.6)     | .949 | 0.3 (0.1, 1.1)                                        | 0.6 (0.1, 2.9) | <.001      |    |
| Arachis hypogaea                                     | 0.1 (0.0, 0.2)     | 0.0 (0.0, 0.1)     | .877 | 0.1 (0.0, 0.2)                                        | 0.1 (0.0, 0.2) | .101       |    |
| Total IgE (kU/L, ImmunoCAP), median (IQR)            | 672 (250, 1942)    | 159 (57, 523)      | <.001 | 279 (98, 648)                                         | 487 (115, 1248) | .018       |    |
| Wheeze in last 12 mo, age < 5 y                       | 1/58 (0.9)         | 2/37 (5.4)         | .188 |                                                       |               |            |    |
| Wheeze in last 12 mo, age ≥ 5 y                       | 24/716 (2.9)       | 5/272 (1.8)        | .308 | 0/200 (0.0)                                           | 200/200 (100.0) |           |    |
| Visible flexural dermatitis                          | 4/780 (0.5)        | 3/345 (0.9)        | .462 | 3/199 (1.5)                                           | 13/198 (6.6)  | .019       |    |
| Rhinitis in last 12 mo                               | 34/774 (4.2)       | 11/309 (3.6)       | .700 | 11/199 (5.5)                                          | 43/198 (21.7) | <.001      |    |
| Urticaria in last 12 mo                              | 98/773 (12.4)      | 11/309 (3.6)       | <.001 | 5/199 (2.5)                                           | 6/198 (3.0)   | .754       |    |
| **Helminth infections**                              |                     |                    |    |                                                       |               |            |    |
| S mansoni (KK)                                       | 187/679 (29.5)     | 14/284 (4.9)       | <.001 | 8/194 (4.1)                                           | 12/184 (6.5)  | .302       |    |
| S mansoni intensity (KK)                             |                     |                    |    |                                                       |               |            |    |
| Uninfected                                           | 492/679 (70.5)     | 270/284 (95.1)     | 186/194 (95.9) | 172/184 (93.5)                                         |               |            |    |
| Low                                                  | 94/679 (14.7)      | 7/284 (2.5)        | 4/194 (2.1) | 7/184 (3.8)                                           |               |            |    |
| Moderate                                             | 53/679 (8.9)       | 4/284 (1.4)        | 3/194 (1.5) | 3/184 (1.6)                                           |               |            |    |
| Heavy                                                | 40/679 (5.8)       | 3/284 (1.1)        | <.001 | 1/194 (0.5)                                           | 2/184 (1.1)   | .328       |    |
| S mansoni (urine CCA)c                                | 590/724 (82.4)     | 108/309 (34.9)     | <.001 |                                                       |               |            |    |
| S mansoni (PCR)c                                     | 310/679 (47.5)     | 43/282 (15.3)      | <.001 |                                                       |               |            |    |
| A lumbricoides (KK)                                  | 2/679 (0.2)        | 0/284 (0)          | 0/194 (0) | 1/184 (0.5)                                           |               |            |    |
| T trichiura (KK)                                     | 44/679 (6.2)       | 4/284 (1.4)        | .002 | 4/194 (2.1)                                           | 2/184 (1.1)   | .456       |    |
| N americanus (PCR)                                   | 72/679 (9.9)       | 12/282 (4.3)       | .016 | 3/194 (1.6)d                                          | 2/184 (1.1)d  | .697       |    |
| S stercoralis (PCR)c                                 | 58/679 (7.5)       | 4/282 (1.4)        | .001 |                                                       |               |            |    |

Schistosoma-specific antibody levels (μg/mL), median (IQR) (Continues)
TABLE 1 (Continued)

| Characteristics                  | Rural survey n/N (%) | Urban survey n/N (%) | p     | Nonasthmatics n/N (%) | Asthmatics n/N (%) | P   |
|----------------------------------|----------------------|----------------------|-------|-----------------------|--------------------|-----|
| SEA-specific IgE                 | 4.6 (3.1, 6.6)       | 2.6 (1.7, 4.4)       | <.001 | 2.4 (1.5, 4.0)        | 2.4 (1.7, 3.9)     | .566|
| SWA-specific IgE                 | 4.9 (3.0, 6.7)       | 2.3 (1.5, 3.4)       | <.001 | 1.9 (1.3, 3.4)        | 2.0 (1.5, 3.3)     | .914|
| SEA-specific IgG                 | 282 (70, 839)        | 27 (0, 90)           | <.001 | 27 (0, 77)            | 26 (0, 68)         | .255|
| SWA-specific IgG                 | 109 (52, 275)        | 39 (18, 65)          | <.001 | 38 (22, 64)           | 39 (22, 60)        | .871|
| SEA-specific IgG                 | 1975 (1061, 3098)    | 739 (599, 1476)      | <.001 | 736 (602, 1318)       | 693 (593, 1117)    | .686|
| SWA-specific IgG                 | 1499 (999, 2140)     | 791 (612, 1200)      | <.001 | 825 (644, 1130)       | 737 (615, 1061)    | .495|

Note: Table shows characteristics for individuals with data on ImmunoCAP®-determined IgE sensitization. Probability values are shown for differences in characteristics between rural and urban survey participants and between asthmatic schoolchildren and nonasthmatic controls. Abbreviations: aslE, allergen-specific IgE; CCA, circulating cathodic antigen; IQR, interquartile range; KK, Kato-Katz; PCR, polymerase chain reaction; SEA, Schistosoma egg antigen; SWA, Schistosoma adult worm antigen.

Table 1 shows participants’ characteristics. Rural participants were on average older than urban participants (P < .001) and more likely to be male. SPT reactivity to Dermatophagoides mix (P = .003) and B tropicalis (P = .025) was higher among urban participants, while total IgE (P < .001) and allergen extract-specific IgE sensitization (ImmunoCAP® concentration ≥ 0.35 kU/L), particularly to cockroach (P < .001), was higher among rural participants. Urticarial rash was more common in rural participants (P < .001), while wheeze, rhinitis and dermatitis were rare in both settings. Rural, compared to urban participants, was more frequently infected with Sm (P < .001), T trichura (P = .002), hookworm (P = .016) and S stercoralis (P = .001) and had higher median levels of SEA- and SWA-specific IgE, IgG and IgG4 (P < .001). Adjusting for age and sex did not impact these differences.

Asthmatics, compared to nonasthmatic controls, had higher prevalence of SPT reactivity, ImmunoCAP® IgE sensitization, dermatitis and rhinitis, and higher total IgE levels (Table 1). ImmunoCAP® IgE sensitization was linked to exposure-related asthma symptoms. For example, of the children who reported dust as a trigger for their asthma symptoms, 65.6% were sensitized (IgE ≥ 0.35 kU/L) to D pteronyssinus, compared to 46.7% who did not report dust as a trigger (P = .009). This difference was not statistically significant for B germanica and A hypogaea-specific IgE sensitization.

Prevalence of helminth infections in the asthma study was low, but concentrations of SEA- and SWA-specific antibodies were moderate, and similar between asthmatics and nonasthmatics (Table 1).

3.2 Overall responses to structures on the ISAC and N-glycan microarray

Figure S3 shows prevalence of sensitization (IgE ≥ 0.3 IU) to allergen components on the ISAC microarray. Among rural participants, sensitization to components on the array was dominated by reactivity to natural components bearing classical CCDs and to insect venom proteins (rPol d 5, rVes v 5, rApi m 1). Among urban participants and nonasthmatics, sensitization patterns were more varied: natural and/or recombinant HDM, venom, food and CCD-bearing components contributed most to sensitization. However, sensitization among asthmatics was dominated by reactivity to major recombinant and natural HDM allergens.

Figure S4 shows average MFIs for structures on the glycan microarray. Although the highest responses were raised predominantly against core β-1,2-xyllose and/or α-1,3-fucose substituted N-glycans in all three studies, responses to other carbohydrate structural elements represented in the array, such as tri-mannose (G99), fucosylated GlcNAc (G111) and galactose-alpha-1,3-galactose (α-1,3-gal) [G112, G113], were also as high.

3.3 Sensitization to allergen extracts does not reflect sensitization to their established major allergenic components, except among asthmatics

In all study settings, sensitization to HDM, German cockroach and peanut extracts (ImmunoCAP® IgE ≥ 0.35 kU/L) was high (Table 1). Fifty five per cent and 43% of rural and urban participants and 73% and 54% of asthmatic schoolchildren and their controls, respectively, were sensitized to at least one of the three extracts. Prevalence of SPT reactivity to each extract was lower than prevalence of IgE sensitization to the extracts of the same allergens (Table 1). The majority of SPT reactive individuals (88% rural, 90% urban, 95% asthmatic and 93% nonasthmatic controls) were also IgE-sensitized to at least one of the three extracts on ImmunoCAP® (data not shown).
However, ISAC microarray showed that sensitization to both natural (non-CCD-bearing) and recombinant forms of established major allergenic components of these extracts was very low among rural and urban survey participants, and among nonasthmatic schoolchildren (Figure 2): 0%-3% (rural), 0%-10% (urban) and 0%-12% (nonasthmatics) of tested participants were sensitized (IgE ≥ 0.30 ISU) to HDM, cockroach and peanut components on ISAC. The picture was strikingly different among asthmatics: 18%-36% were sensitized to HDM allergens (42% to at least one) and 0%-10% to cockroach, but none to peanut components.

### 3.4 Reactivity to CCDs dominates ISAC-determined IgE profiles

Despite the low prevalence of ISAC-determined IgE sensitization to major natural and recombinant components of common allergens in our study settings, many participants mounted responses to components bearing classical CCDs (Figure 3A and B). A higher proportion of rural, compared to urban participants, recognized CCDs (Table S2 and Figure 3A). However, this was statistically significant only for the CCD-bearing components nPhl p 4 and nCry j 1. Conversely, a higher proportion of urban, compared to rural participants, recognized recombinant established major allergens of HDM (Table S2 and Figure 2A), the food components rApi g 1 and rMal d 1 and the cat allergen rFel d 4 (Table S2).

Although reactivity to HDM components was higher among asthmatics compared to controls, reactivity to components bearing classical CCDs and most other allergen components on the array was similar between the two groups (Figure 2 and Table S2).

Many participants also mounted responses to venom proteins (Figure S5). This may represent insect venom sensitization; however, higher reactivity was observed among rural compared to urban participants (Table S2 and Figure S5) and among Sm infected compared...
to uninfected participants (Table S3), possibly reflecting sensitization to Venom-Allergen-Like (VAL) proteins expressed by schistosomes and other helminths. 65,67

3.5 | Reactivity to core β-1,2-xylose/α-1,3-fucose is positively associated with Sm infection and sensitization to allergen extracts, but not sensitization to their established major allergenic components

Cross-reactive carbohydrate determinants expressed by several insect and plant glycoproteins, and by some nematodes and trematodes (such as schistosomes), are typified by presence of α-1,3-linked core fucose and β-1,2-linked core xylose motifs.11,18 We combined the three studies and further explored associations between CCD-specific IgE and Sm infection and atopic sensitization using microarray binding studies of core β-1,2-xylose and α-1,3-fucose substituted N-glycans. Responses to individual core substituted N-glycans were strongly correlated and were combined using PCA. Figure 4A shows scatterplots of PC1 and PC2 loadings (all participants). PC1 was characterized by responses to core β-1,2-xylose and/or α-1,3-fucose substituted N-glycans while PC2 was characterized by responses to nonxylosylated and nonfucosylated glycans. There were positive associations between PC1 scores and (a) S. mansoni infection (Figure 4B) [but not other helminths, data not shown], (b) the rural environment (Figure 4C), (c) HDM, cockroach and peanut extract-sensitization (on ImmunoCAP®) and (d) CCD sensitization [on ISAC] (Figure 4D-G). However, no associations were observed between PC1 scores and sensitization to any of the major natural and recombinant HDM, cockroach and peanut components on ISAC (Figure 4D-F).

3.6 | Inverse associations between reactivity to a subset of core α-1,3-fucosylated N-glycans and asthma, but not for CCD-specific IgE in general

No associations were observed between glycan microarray-assessed IgE response PC scores and asthma or SPT reactivity (Figure 4H-I). Assessment of associations between asthma and responses to individual glycans on the array showed that asthmatics, compared to controls, mounted significantly lower responses to N-glycans carrying core α-1,3-fucose only or in combination with α-1,6-fucose, but not to any other structures on the array (Figure 5).

We did not group asthma cases into “allergic” and “nonallergic” based on ImmunoCAP® IgE sensitization, as our data showed that IgE to allergen extracts reflected sensitization to environmental exposures such as CCDs, and could not accurately define allergic asthma. However, we grouped asthma cases based on SPT reactivity to at least one allergen extract, to assess associations with responses to N-glycans carrying core α-1,3-fucose (Figure S6A). Compared to nonasthmatic controls, both “allergic” (SPT+) and “nonallergic” (SPT–) asthmatics mounted lower responses to core α-1,3-fucose substituted N-glycans. There were no differences in responses between SPT– and SPT+ asthma cases. Similar results were observed when we based on sensitization to at least one recombinant allergen component on the ISAC microarray to group asthma cases into “allergic” (IgE ≥ 0.3 ISU) and “nonallergic” (IgE < 0.3 ISU) [Figure S6B].
FIGURE 4  Associations between anti-glycan IgE responses and atopic sensitization and asthma. Figure shows data combined from all three studies. Panel (A) shows a scatterplot of first (PC1) and second factor (PC2) loadings derived from principal component analysis of IgE responses to 135 synthetic N-glycans. Box-and-whisker plots show associations between PC scores and (B) S. mansoni infection [Kato-Katz and/or PCR, infected n = 88; uninfected n = 154], (C) setting [rural n = 208; urban n = 62], (D) IgE sensitization (ImmunoCAP® IgE ≥ 0.35 kU/L) to crude D. pteronyssinus extract [sensitized n = 145; nonsensitized n = 224] and sensitization (IgE ≥ 0.3 ISU) to any of the dust mite components on the ISAC array [sensitized n = 47; nonsensitized n = 239], (E) IgE sensitization to crude German cockroach extract [sensitized n = 167; nonsensitized n = 201] and to any of the German cockroach components on the ISAC array [sensitized n = 11; nonsensitized n = 275], (F) IgE sensitization to crude peanut (A. hypogaea) extract [sensitized n = 55; nonsensitized n = 314] and to any of the peanut components on the ISAC array [sensitized n = 2; nonsensitized n = 284], (G) IgE sensitization (IgE ≥ 0.30 ISU) to any of the components bearing classical CCDs [sensitized n = 47; nonsensitized n = 239], on the ISAC array, (H) SPT reactivity to any of Dermatophagoides mix, German cockroach or Blomia tropicalis [SPT+ n = 125; SPT- n = 241] and (I) asthma status (asthmatic n = 50; nonasthmatic n = 50). Horizontal lines in the plots represent medians and boxes denote interquartile ranges (IQR). Whiskers were drawn using the Tukey method (1.5 times IQR). Individual points represent outliers (>1.5 times IQR away from median). Associations between PC scores and the various comparison groups were assessed using linear regression analysis in Stata 13.1. Age- and sex-adjusted P values are shown. PC1, principal component 1; PC2, principal component 2; Sm, S. mansoni infection determined by Kato-Katz and/or PCR; ISAC, Immuno Solid-phase Allergen Chip; CCD, cross-reactive carbohydrate determinant; SPT, skin prick test
4 | DISCUSSION

We conducted an assessment of associations between IgE responses at (sub-)molecular level and allergy outcomes among Ugandan rural and urban individuals, and asthmatic schoolchildren and their controls. We found that among rural, urban and nonasthmatic participants, sensitization to extracts from common environmental allergens did not reflect sensitization to their established major allergenic components; rather, many participants recognized CCDs. By contrast, a high proportion of asthmatics were sensitized to both HDM extract and its major components, lending substantial support to increasing evidence that much asthma in tropical LICs is atopic, contrary to earlier perception.68,69 Detailed assessment of IgE reactivity to core β-1,2-xylose and/or α-1,3-fucose (well-known, nonmammalian, “classical” CCDs) using a synthetic glycan microarray revealed strong positive associations with the rural environment and S. mansonii infection and for the first time showed reactivity to a subset of core α-1,3-fucose substituted N-glycans to be negatively associated with asthma.

Allergen extracts contain a mixture of allergenic and nonallergenic components,71 as well as cross-reactive protein and carbohydrate components that are conserved in other environmental antigens such as those from schistosomes.72 This obscures the identity of the molecular drivers, and hence interpretation, of a positive response in vitro to extract-specific IgE blood immunosays (or in vivo to allergen extract-based SPTs). Our results show that this has important implications for diagnosis of atopy, and phenotyping of asthma (and other allergy-related conditions) as “atopic”, in tropical settings and for the use of population attributable fractions to assess the contribution of atopy to allergy-related disease in tropical LICs.

The high prevalence of sensitization to CCDs and to allergen extracts but low sensitization to established major allergenic components in our high-S. mansonii transmission rural setting is reminiscent of previous findings by Hamid et al among Indonesian schoolchildren from areas endemic for soil-transmitted helminths (STH) but not schistosomes.4 These results imply that cross-reactive protein motifs and/or CCDs from environmental antigens other than schistosomes play an important role in allergy epidemiology. Exposure to STH might theoretically contribute; however, as discussed in our previous article on associations between helminth infections and N-glycan-reactivity,70 expression of “classical” CCD epitopes in most STH is not yet well mapped, with STH glycomes understudied compared to the Schistosoma glycome. However, absence of significant associations between anti-CCD

FIGURE 5 Associations between asthma and IgE reactivity to glycans. (A) Heatmap of average log₂-transformed MFIs representing IgE reactivity to each individual glycan structure on the array, in asthmatic (n = 50) versus nonasthmatic schoolchildren (n = 50). *P < .05. (B) Box-and-whisker plots showing MFIs representing IgE reactivity to core α-1,3-fucosylated N-glycan structures. (C) Box-and-whisker plots showing MFIs representing IgE reactivity to core β-1,2-xyllosylated N-glycan structures. Horizontal lines in the plots represent medians, and boxes denote interquartile ranges (IQR). Whiskers were drawn using the Tukey method (1.5 times IQR). Individual points represent outliers (> 1.5 times IQR away from median). The Mann-Whitney U test was conducted within the framework of a Monte Carlo simulation algorithm based on 1000 permutations (in order to adjust for multiple testing), to assess differences between asthmatic and nonasthmatic schoolchildren.

(A) (B) (C)
IgE and infection with any STH (reported here and in our previous study) opposes the notion that STH express "classical" CCDs.

There is evidence showing that cross-sensitization between Schistosoma antigens and peanut, pollen or insect venom allergens is predominantly caused by CCDs. It is likely that previously observed positive associations between Sm and HDM extract-specific IgE in our rural setting are partially attributable to CCD sensitization. In the same population, prevalence of clinical allergies is low, supporting the hypothesis that helminths may protect against allergic effector responses. The role of CCDs in protection against allergy, if any, is unclear. Alpha-1,3-gal has been implicated in meat allergy; however, our studies did not find any evidence of this, despite elevated α-1,3-gal-specific IgE concentrations. Other than α-1,3-gal-specific IgE, carbohydrate-specific IgE rarely, if ever, translates into clinical allergy.

We postulated that elevated IgE responses to specific immunogenic glycans during chronic Sm infection might result in reduced allergic effector responses. Many native allergens occur as glycoproteins; therefore, prior high exposure to specific CCDs (perhaps resulting from Sm infection or other exposures) may prime initial and recall IgE responses to preferentially target-specific CCD rather than the protein epitopes of allergens. Indeed, rural-urban comparisons of responses to components on the ISAC array imply that in our Sm-endemic rural setting, IgE may be less effectively induced against common protein allergens than against CCDs.

In our setting, ISAC-determined anti-CCD IgE was not inversely associated with SPT reactivity or asthma, and PCA of microarray-determined anti-glycan IgE responses suggested no overall association (inverse or otherwise) between asthma and anti-glycan IgE. However, analysis of levels of IgE to individual glycans revealed that reactivity to a subset of core α-1,3-fucose substituted N-glycans was lower among asthmatic schoolchildren compared to their controls, and this was consistent for all N-glycan structural variants. Other than α-1,3-gal-specific IgE, carbohydrate-specific IgE rarely, if ever, translates into clinical allergy.

We found positive associations between asthma and anti-glycan IgE responses suggested no overall association (inverse or otherwise) between asthma and anti-glycan IgE. However, analysis of levels of IgE to individual glycans revealed that reactivity to a subset of core α-1,3-fucose substituted N-glycans was lower among asthmatic schoolchildren compared to their controls, and this was consistent for all N-glycan structural variants. Other than α-1,3-gal-specific IgE, carbohydrate-specific IgE rarely, if ever, translates into clinical allergy.

Overall, our data indicate that, in tropical LICs, IgE to allergen extracts (detected in standard ImmunoCAP® assays) reflects sensitization to a myriad of environmental exposures (absent in high-income countries), such as CCDs, and does not accurately define allergy-related disease phenotypes. In fact, our findings call for studies to investigate whether specific CCD epitopes have a mechanistic role in the protective effect (against asthma) of certain environmental exposures.

ACKNOWLEDGMENTS

We thank Koome sub-county and Entebbe municipality community members for participating in the rural (LaVIISWA) study and the urban survey, respectively. We are grateful to schoolchildren in Entebbe municipality and the surrounding areas in Wakiso District who took part in the asthma case-control study. We also thank all study staff. This work was funded by the Wellcome Trust (grant 095778 awarded to AME for the urban and rural survey, and grant 102512/Z/13/Z awarded to HM for the asthma study). GN was supported by a PhD fellowship from the African Partnership for Chronic Disease Research (APCDR). GN also received a small grant award (GR000904) from the Royal Society of Tropical Medicine and Hygiene (RSTMH) to conduct glycan microarray experiments and a short-term research fellowship from the European Academy of Allergy and Clinical Immunology (EAACI) to conduct ISAC microarray experiments. GN is an honorary fellow, and RES a PhD fellow, of the Makerere University—Uganda Virus Research Institute Centre for Excellence in Infection and Immunity Research and Training (MUII-plus). MUII-plus is funded under the DELTAS Africa Initiative. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant 107743) and the UK Government. The MRC/UVRI and LSHTM Uganda Research Unit is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the ECCTP2 programme supported by the European Union.

CONFLICT OF INTEREST

Gyaviira Nkurunungi reports grants from African Partnership for Chronic Disease Research, Royal Society of Tropical Medicine and Hygiene and European Academy of Allergy and Clinical Immunology,
during the conduct of the study. Harriet Mpairwe reports a grant from the Wellcome Trust, during the conduct of the study. Alison Elliott reports grants from the Wellcome Trust and the Medical research Council, UK, during the conduct of the study. Richard Sanya reports a grant from Alliance for Accelerating Excellence in Science in Africa (AESA), outside the submitted work. Ronald van Ree reports personal fees from HAL Allergy BV and Thermo Fisher Scientific, outside the submitted work, and has consultant agreements with HAL Allergy BV, Citeq BV and Angany Inc. The rest of the authors declare that they have no conflicts of interest.

ETHICAL APPROVAL

This work was approved by ethics committees of Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, and Uganda National Council for Science and Technology. Written informed consent was obtained from all participants and/or their legal guardians. Assent was obtained from children ≥8 years.

ORCID

Gyaviira Nkurunungi https://orcid.org/0000-0003-4062-9105
Emily L. Webb https://orcid.org/0000-0002-4019-7456

REFERENCES

1. Soto-Quiros M, Avila L, Platts-Mills TAE, et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. J Allergy Clin Immunol. 2012;129(6):1499-1505.
2. Spanier AJ, Hornung RW, Kahn RS, Lierl MB, Lanphear BP. Seasonal variation and environmental predictors of exhaled nitric oxide in children with asthma. Pediatr Pulmonol. 2008;43(6):576-583.
3. Crane J, Lampshire P, Wickens K, et al. Asthma, atopy and exhaled nitric oxide in a cohort of 6-yr-old New Zealand children. Pediatr Allergy Immunol. 2012;23(1):59-64.
4. Hamid F, Versteeg SA, Wiria AE, et al. Molecular diagnostics and environmental predictors of wheezing among asymptomatic children. J Allergy Clin Immunol. 2017;140(4):1196-1199.
5. Sanya R, Antwi-Agyei P, Akompong E, et al. The role of protein glycosylation in allergy. Int Arch Allergy Immunol. 2011;154(2):168-176.
6. Santiago HC, Bennur S, Boyd A, Eberhard M, Nutman TB. Molecularly defined immune epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeﬁciency virus type 1 infection. J Virol. 2012;86(4):2153-2164.
7. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
8. Fotisch K, Altmann F, Haustein D, Vieths S. Involvement of carbohydrates in the histamine release from basophils. PLoS Negl Trop Dis. 2012;6(2):e1510.
9. Nakamura Y, Hibi T, Nishida T, et al. The role of O-glycosylation in IgE-mediated allergy. Glycobiology. 2000;10(8):613-621.
10. Oyelaran O, McShane LM, Dodd L, Gildersleeve JC. Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res. 2009;8(9):4301-4310.
11. Navia JA, Stroop M, Wilmshurst J, et al. Mapping of the glycans from the egg glycoproteins of Schistosoma mansoni and Schistosoma japonicum: identification of novel core structures and terminal sequences. Glycobiology. 1997;7(5):663-677.
12. Hamid F, Wiria AE, Versteeg SA, et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. J Allergy Clin Immunol. 2012;129(6):1499-1505.
13. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
14. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
15. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
16. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
17. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
18. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
19. van Diepen A, Smit CH, van Egmond L, et al. Differential anti-glycan antibodies in schistosome-infected humans. PLoS Negl Trop Dis. 2012;6(11):e1922.
32. Westphal S, Kolarich D, Foetisch K, et al. Molecular characterization and allergenic activity of Lyc e 2 (beta-fructofuranosidase), a glycosylated allergen of tomato. *Eur J Biochem*. 2003;270(6):1327-1337.

33. Commins SP, Platts-Mills TA. Delayed anaphylaxis to red meat in patients with IgE specific for galactose-alpha-1,3-galactose (alpha-gal). *Curr Allergy Asthma Rep*. 2013;13(1):72-77.

34. van der Veen MJ, van Ree R, Aalberse RC, et al. Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins. *J Allergy Clin Immunol*. 1997;100(3):327-334.

35. Amoah AS, Obeng BB, Larbi IA, et al. Peanut-specific IgE antibodies in asymptomatic Ghanaian children possibly caused by carbohydrate determinant cross-reactivity. *J Allergy Clin Immunol*. 2013;132(3):639-647.

36. Sanya RE, Nkurunungi G, Hoek Spaans R, et al. The Impact of Intensive Versus Standard Anthelmintic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial. *Clin Infect Dis*. 2018;ciy761.

37. Nkurunungi G, Lubuya L, Versteeg SA, et al. Do helminth infections underpin urban-rural differences in risk factors for allergy-related outcomes? *Clin Exp Allergy*. 2019;49(5):663-676.

38. Mpairwe H, Namutebi M, Nkurunungi G, et al. Risk factors for asthma among schoolchildren who participated in a case-control study in urban Uganda. *Elife*. 2019;8:e4996.

39. Nampijja M, Webb EL, Kaweesa J, et al. The Lake Victoria island intervention study on worms and allergy-related diseases (LaVIISWA): study protocol for a randomised controlled trial. *Trials*. 2015;16(1):187.

40. Webb EL, Nampijja M, Kaweesa J, et al. Helminths are positively associated with atopy and wheeze in Ugandan fishing communities: results from a cross-sectional survey. *Allergy*. 2016;71(8):1156-1169.

41. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW. ISAC Phase Three Manual. Auckland: ISAC International Data Centre; 2000.

42. Mpairwe H, Tumwesige P, Namutebi M, et al. Asthma control and management among schoolchildren in urban Uganda: results from a cross-sectional study [version 1; peer review: 1 approved with reservations]. *Wellcome Open Res*. 2019;4:168.

43. Mpairwe H, Muhangi L, Ndibazza J, et al. Skin prick test reactivity to common allergens among women in Entebbe, Uganda. *Trans R Soc Trop Med Hyg*. 2008;102(4):367-373.

44. Williams HC. How Do I Define Atopic Eczema? A Practical manual for researchers wishing to define atopic eczema. http://www.nottingham.ac.uk/~mzzfaq/dermatologyeczema/contents.html. Accessed February 6, 2018.

45. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool smear technique in Schistosomiasis mansoni. *Rev Inst Med Trop Sao Paulo*. 1972;14(6):397-400.

46. Verweij JJ, Brienen EA, Ziem J, Yelifarli L, Polderman AM, Van Lieshout L. Simultaneous detection and quantification of Ancylostoma duodenale, Necator americanus, and Oesophagostomum bifurcum in fecal samples using multiplex real-time PCR. *Am J Trop Med Hyg*. 2007;77(4):685-690.

47. Verweij JJ, Canales M, Polman K, et al. Molecular diagnosis of Strongyloides stercoralis in faecal samples using real-time PCR. *Trans R Soc Trop Med Hyg*. 2009;103(4):342-346.

48. ImmunoCAP Specific IgE. http://www.phadia.com/da/Products/Allergy-testing-products/ImmunoCAP-Lab-Tests/slgE/. Accessed 21 September 2018.

49. ImmunoCAP ISAC – When you need the bigger picture in allergy. http://www.phadia.com/da/Products/Allergy-testing-products/ImmunoCAP-ISAC/. Accessed 21 September 2018.

50. ISAC: Frontline biochip technology - features and benefits in allergy diagnostics. http://www.phadia.com/Global/A%20Document%20Library/Allergy/Promotion%20Material/ImmunoCAP%20ISAC/ImmunoCAP-ISAC-Technical-brochure.pdf. Accessed 30 December 2019.

51. van Hage M, Schmid-Grendelmeier P, Skevaki C, et al. Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study. *Clin Chem Lab Med*. 55(2017):571.

52. Curin M, Garib V, Valenta R. Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment. *Ann Allergy Asthma Immunol*. 2017;119(3):201-209.

53. Holzweber F, Svehla E, Fellner W, et al. Inhibition of IgE binding to cross-reactive carbohydrate determinants enhances diagnostic selectivity. *Allergy*. 2013;68(10):1269-1277.

54. Minami T, Fukutomi Y, Lidholm J, et al. IgE Abs to Der p 1 and Der p 2 as diagnostic markers of house dust mite allergy as defined by a bronchoprovocation test. *Allergol Int*. 2015;64(1):90-95.

55. Sohn MH, Kim K-E. The cockroach and allergic diseases. *Allergy Asthma Res*. 2012;4(5):264-269.

56. ImmunoCAP ISAC – When you need the bigger picture in allergy. http://www.phadia.com/da/Products/Allergy-testing-products/ImmunoCAP-ISAC/. Accessed 21 September 2018, 2018.

57. Phadia Multiplexing Diagnostics GmbH, Wien, Austria, and Phadia AB, Uppsala, Sweden; 2009. http://www.phadia.com/Global/Corporated%20Allergy/Fds/FD/Assay%20Kit%20IgE/FD-Imunocap-AP-ICAP-20-01-02-3-RUO.pdf.

58. Echeverria B, Serna S, Achilli S, et al. Chemoenzymatic Synthesis of N-glycan Positional Isomers and Evidence for Branch Selective Binding by Monoclonal Antibodies and Human C-type Lectin Receptors. *ACS Chem Biol*. 2018;13(8):2269-2279.

59. Brzezicka K, Echeverria B, Serna S, Van Diepen A, Hokke CH, Reichardt NC. Synthesis and microarray-assisted binding studies of core xylose and fucose containing N-glycans. *ACS Chem Biol*. 2015;10(5):1290-1302.

60. Amoah AS, Asuming-Brempong EO, Obeng BB, et al. Identification of dominant anti-glycan IgE responses in school children by glycan microarray. *J Allergy Clin Immunol*. 2018;141(3):1130-1133.

61. van Diepen A, van der Plas AJ, Kozak RP, Royle L, Dunne DW, Hokke CH. Development of a Schistosoma mansoni shotgun O-glycan microarray and application to the discovery of new antigenic schistosome glycan motifs. *Int Parasitol*. 2015;45(7):465-475.

62. Yang YY, Li XH, Brzezicka K, et al. Specific anti-glycan antibodies are sustained during and after parasite clearance in Schistosoma japonicum-infected rhesus macaques. *PLoS Negl Trop Dis*. 2017;11(2):e0005339.

63. Nkurunungi G, Kabagenyi J, Nampijja M, Sanya RE, Walusimbi B, Nussuuna J, Webb EL, Elliott A. Schistosoma mansoni -specific immune responses and allergy in Uganda. *Parasite Immunology*. 2018;40(1):e12506.

64. Jiang Y, Zhang L, Kong F, et al. MCPerm: A Monte Carlo Permutation Method for Accurately Correcting the Multiple Testing in a Meta-Analysis of Genetic Association Studies. *PLoS One*. 2014;9(2):e89212.

65. Chen J, Hu X, He S, et al. Expression and immune response analysis of Schistosoma japonicum VAL-1, a homologue of vespid venom allergens and Ancylostoma secreted proteins. *Mol Biochem Parasitol*. 2001;118(1):89-96.
68. Flohr C, Weiland SK, Weinmayr G, et al. The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two. J Allergy Clin Immunol. 2008;121(1):141-147.

69. Weinmayr G, Weiland SK, Bjorksten B, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med. 2007;176(6):565-574.

70. Nkurunungi G, van Diepen A, Nassuuna J, et al. Microarray assessment of N-glycan-specific IgE and IgG profiles associated with Schistosoma mansoni infection in rural and urban Uganda. Sci Rep. 2019;9(1):3522.

71. Sander I, Fleischer C, Meurer U, Bruning T, Raulf-Heimsoth M. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy. 2009;64(10):1486-1492.

72. Hamid F, Amoah AS, van Ree R, Yazdanbakhsh M. Helminth-induced IgE and protection against allergic disorders. Curr Top Microbiol Immunol. 2015;388:91-108.

73. Igetei JE, El-Faham M, Liddell S, Doenhoff MJ. Antigenic cross-reactivity between Schistosoma mansoni and peanut: a role for cross-reactive carbohydrate determinants (CCDs) and implications for the hygiene hypothesis. Immunology. 2017;150(4):506-517.

74. Igetei JE, El-Faham M, Liddell S, Schramm G, Doenhoff MJ. Antigenic cross-reactivity between Schistosoma mansoni and pollen allergens from the birch tree (Betula verrucosa) and Timothy grass (Phleum pratense): involvement of shared glycan epitopes and implications for the hygiene hypothesis. Int J Parasitol. 2018;48(5):345-357.

75. Wilbers RHP, Westerhof LB, van Noort K, et al. Production and glyco-engineering of immunomodulatory helminth glycoproteins in plants. Sci Rep. 2017;7:45910.

76. Pekkanen J, Pearce N. Defining asthma in epidemiological studies. Eur Respir J. 1999;14(4):951-957.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Nkurunungi G, Mpairwe H, Versteeg SA, et al. Cross-reactive carbohydrate determinants-specific IgE obscures true atopy and exhibits α-1,3-fucose epitope-specific inverse associations with asthma. Allergy. 2021;76:233-246. https://doi.org/10.1111/all.14469